Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE BRAF and MEK1/2 inhibitors are effective in melanoma but resistance inevitably develops. 31727888 2019
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 GeneticVariation disease BEFREE Combinatorial inhibition of MEK1/2 and CDK4/6 is currently undergoing clinical investigation in NRAS-mutant melanoma. 30819666 2019
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE It inhibited colorectal cancer and melanoma cell proliferation much more effectively than its negative control MS432N (<b>24</b>), and its effect was phenocopied by MEK1/2 knockdown. 31730343 2019
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE A MEK1/2 inhibitor, binimetinib is promising as a therapeutic agent for malignant melanoma with N-RAS mutation. 31129802 2019
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced <i>NRAS</i>- or <i>BRAF</i>-mutated melanoma. 30956763 2019
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE Together, these pathways provide a way to activate MAPK signaling downstream of BRAF and MEK1 inhibitors, which are commonly used to treat melanoma. 30543563 2019
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE ERK1 is the immediate downstream target of MEK1/2, which is druggable with trametinib, an approved therapeutic for melanoma. 30804427 2019
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE Recent clinical and therapeutic success with RAF and MEK1/2 inhibitors has revolutionized the existing treatment schemes for previously incurable cancers like melanomas. 31662208 2019
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE While the role of the BRAF-MEK1/2-ERK1/2 pathway in melanoma is well established, the involvement of mitogen-activated protein kinases MEK5-ERK5 remains poorly explored. 29483645 2018
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE Coupling MEK1/2 inhibitors with B-Raf inhibitors is more effective in treating such melanomas and dual therapy is now the standard of care. 30118796 2018
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE The mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) inhibitor trametinib has shown promising therapeutic effects on melanoma, but its efficacy on colorectal cancer (CRC) is limited. 28756770 2017
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 GeneticVariation disease BEFREE In patients with BRAF-mutated melanoma specific inhibitors of BRAF<sup>V600E</sup> and MEK1/2 frequently induce initial tumor reduction, frequently followed by relapse. 28720543 2017
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma. 28387310 2017
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE phase II and III clinical trials demonstrated modest anti- tumor activity of Binimetinib (MEK162) - a potent allosteric inhibitor of MEK1 and MEK2- in patients with advanced NRAS mutant melanoma. 28919996 2017
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE Corrigendum: Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma. 28548101 2017
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE MEK1/2 and BRAF<sup>V600E</sup> inhibitors are used to treat BRAF<sup>V600E</sup>-positive melanoma, with other cancers under evaluation. 28986383 2017
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 GeneticVariation disease BEFREE Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma. 28112278 2016
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 GeneticVariation disease BEFREE Taken together, our data indicate that preexisting MEK1(P124) mutations are associated with a reduced response to BRAF inhibitor therapy and identify a subset of patients with BRAF-mutant melanoma likely to benefit from combination therapies involving MEK or ERK inhibitors. 25370473 2015
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 GeneticVariation disease BEFREE This MEK1(T55delins) (RT) mutation could be traced back to a fraction of the pre-treatment lesion and not only provided protection against vemurafenib but also promoted local invasion of transplanted melanomas. 26105199 2015
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 Biomarker disease BEFREE PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. 25472943 2015
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 AlteredExpression disease BEFREE Single treatment of BRAF mutant melanoma cell lines with vemurafenib or dabrafenib (BRAF inhibitors) alone or in combination with trametinib (MEK1/2 inhibitor) resulted in overexpression of Mcl-1. 26497853 2015
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 GeneticVariation disease BEFREE In recent years, intracellular signal transduction via RAS-RAF-MEK-ERK has been successfully targeted in new treatment approaches for melanoma using small molecule inhibitors against activated BRAF (V600E mutation) and activated MEK1/2. 25654738 2015
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 CausalMutation disease CLINVAR Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model. 24448821 2014
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 GeneticVariation disease BEFREE Our data confirming that MEK2(C125S), but not the synonymous MEK1(C121S) protein, confers resistance to combination therapy highlight the functional differences between these kinases and the preponderance of MEK2 mutations in combination therapy-resistant melanomas. 25452114 2014
Entrez Id: 5604
Gene Symbol: MAP2K1
MAP2K1
0.700 GeneticVariation disease BEFREE We found that the acquired MEK1-C121S mutation in BRAF-V600E mutant melanoma conferred resistance to both vemurafenib and selumetinib but not E6201. 24448821 2014